Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas.
Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas.
复制标题
DOI：
--
复制
发表时间：
1982
期刊：
影响因子：
11.2
通讯作者：
T. R. Jones;E. Ruoslahti;S. Schold;D. Bigner
中科院分区：
文献类型：
--
作者：
T. R. Jones;E. Ruoslahti;S. Schold;D. Bigner
摘要：纤连蛋白（FN）是一种具有粘附和调理特性的细胞外基质糖蛋白，在正常和肿瘤性人类中枢神经系统组织中进行了检测。通过免疫组织化学检测，在正常成人和胎儿大脑中，FN 表达仅限于脉管系统。神经元和神经胶质细胞没有染色。检查的 10 个神经胶质瘤中有 9 个的 FN 表达与正常胎儿和成人大脑中的 FN 表达在质量上相似，因为它仅限于血管。然而，在一种情况下，存在 FN 的间质表达。四种肿瘤表现出不同程度的成纤维细胞过度生长，其中检测到含有 FN 的细胞。通过双标记荧光素-罗丹明荧光技术，对 8 个无胸腺小鼠源性间变性人神经胶质瘤的冰冻切片同时对 FN 和神经胶质纤维酸性蛋白 (GFAP)（一种神经胶质细胞和神经胶质瘤标记物）进行染色。八个肿瘤中的七个表达 FN，八个肿瘤中的七个表达 GFAP，八个肿瘤中的六个表达两者。 FN 被检测为细胞间的细原纤维和斑点，而 GFAP 则呈现为均匀的细胞内荧光。在肿瘤的许多区域，细胞群同时表达 FN 和 GFAP。检查了 11 种人神经胶质瘤来源的细胞系的 FN 和 GFAP 表达。在两个细胞系中，存在同时含有GFAP和FN的细胞。无胸腺小鼠源性肿瘤是通过将产生 FN 的神经胶质瘤衍生细胞系注射到无胸腺小鼠体内而形成的。监测了人 FN 血浆水平，一些大于 1.0 g 的肿瘤产生了可在血浆中检测到的 FN，从而证明肿瘤产生的 FN 可以从人神经胶质瘤衍生细胞中脱落，数量足以在血流中检测到。这些数据表明，在人类间变性神经胶质瘤中，FN 表达在无胸腺小鼠源性肿瘤中出现的频率最高。 GFAP 阳性培养细胞也能够表达 FN。原始肿瘤很少表达可检测量的 FN。 FN 表达异质性的生物学基础取决于所研究的个体组织的性质、其细胞环境（即体内或体外）及其与肿瘤相关的状态。
Abstract The expression of fibronectin (FN), an extracellular matrix glycoprotein with adhesive and opsonic properties, was examined in normal and neoplastic human central nervous system tissues. In both normal adult and fetal brain, FN expression, as detected by immunohistochemistry, was restricted to the vasculature. Neurons and glia did not stain. FN expression in nine of 10 gliomas examined was qualitatively similar to that in normal fetal and adult brain in that it was confined to the blood vessels. Nevertheless, in one case, there was interstitial expression of FN. Four tumors exhibited varying degrees of fibroblastic overgrowth in which cells containing FN were detected. Frozen sections of eight athymic mouse-borne anaplastic human gliomas were stained simultaneously by a double-label fluorescein-rhodamine fluorescence technique for both FN and glial fibrillary acidic protein (GFAP), a glial and glioma marker. Seven of eight tumors expressed FN, seven of eight expressed GFAP, and six of eight expressed both. FN was detected as fine fibrils and specks between cells while GFAP presented as a homogeneous intracellular fluorescence. In many areas of the tumors, groups of cells expressed both FN and GFAP. Eleven human glioma-derived cell lines were examined for both FN and GFAP expression. In two cell lines, there were cells which contained both GFAP and FN simultaneously. Athymic mouse-borne tumors were developed by the injection of an FN-producing glioma-derived cell line into athymic mice. Human FN plasma levels were monitored, and some tumors larger than 1.0 g produced FN which was detectable in the plasma, thereby demonstrating that tumor-produced FN can be shed from human glioma-derived cells in sufficient amounts to be detectable in the bloodstream. These data show that FN expression in anaplastic human gliomas is seen with the greatest frequency in athymic mouse-borne tumors; GFAP-positive cultured cells are also capable of FN expression. The original tumors rarely express detectable amounts of FN. The biological basis for this heterogeneity of FN expression rests in the nature of the individual tissue studied, its cellular environment (i.e., in vivo or in vitro), and its status with regard to neoplasia.